EPIDEMIOLOGICAL ASPECTS OF IN-STENT THROMBOSIS AND RESTENOSIS OF CORONARY ARTERIES IN PATIENTS WITH PREVIOUS REVASCULARIZATION AFTER CORONAVIRUS INFECTION
Introduction. Understanding the risk factors for thrombosis and in-stent restenosis is of particular importance for the people at risk for adverse outcomes, especially in older patients with previously revascularized myocardium and comorbid conditions including coronavirus infection.
The purpose of the study was to assess the risk factors for restenosis and in-stent thrombosis of the coronary artery in patients with previously revascularized myocardium who had suffered coronavirus infection.
Materials and methods. We conducted a retrospective epidemiological study of the prevalence of in-stent thrombosis and restenosis, calculating the odds ratio for each risk factor in a continuous sample of individuals who underwent coronary angiography followed by myocardial revascularization with stenting for the period from May 2020 to May 2023. During the entire study period, 7,738 people underwent coronary angiography, of which 4,619 patients received coronary artery stenting according to indications. Statistical analysis was performed using SPSS version 20.0 software (IBM Ireland Product Distribution Limited, Ireland). To assess the contribution of each risk factor to the development of late postoperative complications, odds ratios were calculated.
Results. The presence of diabetes mellitus more than doubles the chances of developing restenosis and coronary artery stent thrombosis; for arterial hypertension, this rate was 1.5. Male gender is associated with a 2.9-fold increased chance of in-stent restenosis. For D-dimer, troponin, ALT, AST, creatinine, C-reactive protein and CPK, the odds of coronary artery restenosis increased more than twice (p<0.001). Age and left ventricular ejection fraction did not play a role in the development of the pathology under study. The maximum increase in the odds of coronary artery restenosis was observed in patients who had coronavirus infection – 3.176 (p <0.001).
Conclusion. Maximum efforts should be made to prevent restenosis, taking into account modifiable risk factors and the possibility of an individualized approach to treatment.
Gulnara B. Batenova1, https://orcid.org/0000-0003-3198-1860
Lyudmila M. Pivina1, https://orcid.org/0000-0002-8035-4866
Evgeny I. Dedov3, https://orcid.org/0000-0002-9118-3708
Diana G. Ygiyeva1, https://orcid.org/0000-0001-8391-8842
Galiya А. Аlibayeva2, https://orcid.org/0000-0002-1503-4663
Zhansaya Т. Aukenova1, https://orcid.org/0009-0001-3591-8175
Andrey Yu. Orekhov1, https://orcid.org/0000-0001-7201-1399
Assylzhan М. Messova1, https://orcid.org/0000-0001-5373-0523
Maksim R. Pivin1, https://orcid.org/ 0000-0001-7206-8029
Zhanar М. Urazalina1, https://orcid.org/0000-0002-4494-6565
1 NCJSC “Semey Medical University”, Semey, Republic of Kazakhstan;
2 Emergency Hospital, Semey, Republic of Kazakhstan;
3 Russian National Research Medical University named after. N.I. Pirogov, Moscow, Russian Federation.
1. Batenova G., Pivina L., Dedov E., Dyussupov A., Zhumanbayeva Z., Smail Y., Belikhina T., Pak L., Ygiyeva D. Restenosis of Coronary Arteries in Patients with Coronavirus Infection: Case Series // Case Rep Med. 2023. Р. 3000420.
2. Buccheri D., Piraino D., Andolina G., Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment // J Thorac Dis. 2016. Vol 8(10). E1150-E1162.
3. Byrne R.A., Stone G.W., Ormiston J., Kastrati A. Coronary balloon angioplasty, stents, and scaffolds // Lancet. 2017. Vol 390(10096). Р.781-792.
4. Cornelissen A., Vogt F.J. The effects of stenting on coronary endothelium from a molecular biological view: Time for improvement? // J Cell Mol Med. 2019. Vol 23(1). Р.39-46.
5. Hauguel-Moreau M., Prati G., Pillière R., Beaune S., Loeb T., Sawczynski B., Aïdan V., Hergault H., Ouadahi M., Szymanski C., Dubourg O., Mansencal N. Impact of two COVID-19 national lockdowns on acute coronary syndrome admissions // Coron Artery Dis. 2022. Vol 33(4). Р.333-334.
6. Lee O.H., Hong S.J., Ahn C.M., Kim J.S., Kim B.K., Ko Y.G., Choi D., Jang Y., Hong M.K. The Incidence of Non-Cardiac Surgery in Patients Treated With Drug-Eluting Stents According to Age // J Invasive Cardiol. 2019. Vol 31(2). E9-E14.
7. Li M., Hou J., Gu X., Weng R., Zhong Z., Liu S. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China // Eur J Med Res. 2022. Vol.27. (1). Р.12.
8. Liu D., Xue Z., Qi J., Yin L., Duan B., Wu L., Yang K., Gao B., Cao Q., Mi J. Risk factors for instent restenosis of sirolimus-coated stents in coronary intervention for patients with unstable angina // Sci Rep. 2024. Vol 14(1). Р. 2537.
9. Montaseri M., Golchin Vafa R., Attar A., Ali Hosseini S., Kojuri J. Stent thrombosis during COVID-19 pandemic: A case series // Clin Case Rep. 2022. Vol 10(5). e05872.
10. Pleva L., Kukla P., Hlinomaz O. Treatment of coronary in-stent restenosis: a systematic review // J Geriatr Cardiol. 2018. Vol 15(2). Р.173-184.
11. Zaher N., Sattar Y., Mahmood S., Vacek T., Alraies M.C. COVID-19 Infection Complicated by a Complete Occlusion of the Left Circumflex Artery With Acute Restenosis After Drug-Eluting Stent Placement // Cureus. 2020. Vol 12(9). e10708.
Количество просмотров: 3389
Библиографическая ссылка
Batenova G.B., Pivina L.M., Dedov E.I., Ygiyeva D.G., Аlibayeva G.А., Aukenova Zh.Т., Orekhov A.Yu., Messova A.М., Pivin M.R., Urazalina Zh.М. Epidemiological aspects of in-stent thrombosis and restenosis of coronary arteries in patients with previous revascularization after coronavirus infection // Nauka i Zdravookhranenie [Science & Healthcare]. 2024, Vol.26 (2), pp. 97-103. doi 10.34689/SH.2024.26.2.013Похожие публикации:
ПОСТ-COVID-19-СИНДРОМ: СИМПТОМЫ И ФАКТОРЫ РИСКА
ПРИМЕНЕНИЕ КЛАССИФИКАЦИИ РОБСОНА ДЛЯ ОЦЕНКИ ПОКАЗАТЕЛЯ ЧАСТОТЫ КЕСАРЕВА СЕЧЕНИЯ И ПОИСКА ВОЗМОЖНОСТЕЙ ЕГО СНИЖЕНИЯ
СУЩЕСТВУЮЩАЯ ПРАКТИКА УХОДА ЗА ЛЮДЬМИ С ДЕМЕНЦИЕЙ
ЭМБОЛИЗАЦИЯ МАТОЧНЫХ АРТЕРИЙ ПРИ ПОЗДНЕМ ПОСЛЕРОДОВОМ КРОВОТЕЧЕНИИ НА ФОНЕ МЕТРОЭНДОМЕТРИТА: КЛИНИЧЕСКИЙ СЛУЧАЙ
ПРОБИОТИКИ КАК ДОПОЛНИТЕЛЬНОЕ ЛЕЧЕНИЕ РЕВМАТОИДНОГО АРТРИТА. ОБЗОР ЛИТЕРАТУРЫ.